Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
Hologic (HOLX) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Lower sales of COVID-19 assays and supply chain challenges drag Hologic's (HOLX) top line down.
Catalent (CTLT) Q1 Earnings Lag Estimates, FY23 View Cut
by Zacks Equity Research
Catalent (CTLT) records robust first-quarter fiscal 2023 results of its Pharma and Consumer Health segment despite overall soft performance.
IDEXX (IDXX) Q3 Earnings Beat Estimates, 2022 EPS View Down
by Zacks Equity Research
IDEXX's (IDXX) Q3 top-line performance rides on strong CAG Diagnostics recurring revenue growth.
Henry Schein (HSIC) Q3 Earnings In Line, 2022 Sales View Down
by Zacks Equity Research
Severe currency headwinds and lower sales of PPE and COVID-19 test kits affect Henry Schein's (HSIC) top line in Q3.
Teleflex (TFX) Q3 Earnings Top Estimates, Adjusted EPS View Cut
by Zacks Equity Research
For UroLift, Teleflex (TFX) currently assumes 2022 revenues to be roughly $320 million, down from the prior guidance of $335 million.
Abiomed (ABMD) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.
Avantor (AVTR) Q3 Earnings Top Estimates, 2022 EPS View Cut
by Zacks Equity Research
Avantor's (AVTR) robust performance across the majority of its segments drives its Q3 sales, despite business challenges.
Integer Holdings (ITGR) Q3 Earnings Beat, 2022 View Lowered
by Zacks Equity Research
Integer Holdings' (ITGR) third-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.
DaVita (DVA) Q3 Earnings Lag Estimates, 2022 EPS View Cut
by Zacks Equity Research
DaVita's (DVA) Q3 performance gets a boost from strength in both its segments.
Merit Medical (MMSI) Q3 Earnings Beat, FY22 View Revised
by Zacks Equity Research
Merit Medical (MMSI), in the third quarter, benefits from revenue growth in both its segments and the majority of product categories within its Cardiovascular unit.
Merit Medical (MMSI) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 20.75% and 5.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Merit Medical (MMSI) Launches New Soft Tissue Biopsy System
by Zacks Equity Research
Merit Medical's (MMSI) launch of the TEMNO Elite Soft Tissue Biopsy System will boost its portfolio of biopsy devices.
Merit Medical's (MMSI) Latest Launch to Boost Patient Care
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its portfolio is expected to ease access to difficult anatomy in the peripheral vasculature, thereby serving a wider patient pool.
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Why Is Henry Schein (HSIC) Down 1.5% Since Last Earnings Report?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merit Medical (MMSI) Q2 Earnings Beat, FY22 View Revised
by Zacks Equity Research
Merit Medical (MMSI), in the second quarter, benefits from revenue growth in both its segments and from all product categories within its Cardiovascular unit.
Merit Medical (MMSI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 25.86% and 4.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Merit Medical's (MMSI) New Launch to Improve Patient Outcome
by Zacks Equity Research
Merit Medical's (MMSI) latest launch will likely aid in precisely targeting affected tissues, thereby resulting in more successful surgeries and improved patient outcomes.
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Here's Why Merit Medical (MMSI) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) due to its strong product portfolio.
Why Is Merit Medical (MMSI) Down 4.3% Since Last Earnings Report?
by Zacks Equity Research
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merit Medical (MMSI) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merit Medical (MMSI) Q1 Earnings Beat, FY22 View Unchanged
by Zacks Equity Research
Merit Medical (MMSI), in the first quarter, benefits from revenue growth in both its segments and from all of the product categories within its Cardiovascular unit.